(Endometrial Cancer) Verzenio + Letrozole Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On September 29, 2022, Panagiotis A. Konstantinopoulos et al. from Dana-Farber Cancer Institute published in the medical journal Journal of Clinical Oncology the efficacy and safety results of Verzenio (abemaciclib) plus Letrozole as treatment for patients with estrogen receptor-positive recurrent endometrial cancer in a Phase II clinical trial at Dana-Farber Cancer Institute.
This Phase II clinical trial enrolled 30 patients with estrogen receptor-positive recurrent endometrial cancer (N=30). They received Verzenio plus Letrozole therapy, with the primary endpoints being objective response rate (ORR) and 6-month progression-free survival rate (PFS).
The results showed that the primary endpoint ORR was 30%. The other primary endpoint, median progression-free survival, was 9.1 months. The 6-month progression-free survival rate was 55.6%, and the median duration of response was 7.4 months. Regarding safety, the most common Grade 3 or higher adverse events observed in the majority of patients were neutropenia (20%) and anemia (17%).
Based on the Phase II trial results, Panagiotis A. Konstantinopoulos et al. concluded: Patients with estrogen receptor-positive recurrent endometrial cancer treated with Verzenio plus Letrozole demonstrated durable and promising anti-tumor activity.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.22.00628
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4